US2021052635A1PendingUtilityA1

Polymers for reversing heparin-based anticoagulation

Assignee: UNIV BRITISH COLUMBIAPriority: Jun 1, 2011Filed: Aug 9, 2019Published: Feb 25, 2021
Est. expiryJun 1, 2031(~4.8 yrs left)· nominal 20-yr term from priority
C08L 71/02A61M 2202/0021A61M 2202/0478A61K 47/34A61K 31/785B01D 15/36A61K 9/0014C08G 2340/00A61K 9/06A61K 31/795A61K 31/765C08G 73/024A61M 2202/0413A61M 1/3675A61M 1/3679
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.

Claims

exact text as granted — not AI-modified
1 . A method of counteracting heparin in a subject, the method comprising:
 administering a heparin binding polymer to the subject, wherein the heparin binding polymer comprises:
 a core unit, wherein the core unit comprises a C 1-18  alkyl substituted with three or more of —OR 1 ,
 wherein each R 1  is independently selected from a polymer segment having monomer units of Formula (III): 
 
   
       
         
           
           
               
               
           
         
         
           
             
               wherein n is an integer from 1 to 10,000, 
               wherein each R 2  is independently selected from a hydrogen, carbon, a cationic moiety, R 1 , and a polymer segment of Formula (IV): 
             
           
         
       
       
         
           
           
               
               
           
         
         
           
             
               wherein each R 3  is independently selected from an oxygen cationic moiety, a hydroxyl, and a polymer segment of Formula (IV), 
               wherein m is an integer from 1 to 10,000, 
               wherein each R 4  is independently selected from a C 1-6  alkoxy, and 
             
           
         
         wherein the heparin binding polymer comprises 1 to 300 cationic moieties.

Join the waitlist — get patent alerts

Track US2021052635A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.